-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sparsentan in Focal Segmental Glomerulosclerosis (FSGS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sparsentan in Focal Segmental Glomerulosclerosis (FSGS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sparsentan in Focal Segmental Glomerulosclerosis (FSGS) Drug Details: Sparsentan (Filspari)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VB-119 in Focal Segmental Glomerulosclerosis (FSGS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VB-119 in Focal Segmental Glomerulosclerosis (FSGS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VB-119 in Focal Segmental Glomerulosclerosis (FSGS) Drug Details: VB-119 is...
-
Product Insights
Focal Segmental Glomerulosclerosis (FSGS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Focal Segmental Glomerulosclerosis (FSGS) - Drugs In Development, 2023’, provides an overview of the Focal Segmental Glomerulosclerosis (FSGS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Focal Segmental Glomerulosclerosis (FSGS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Abiprubart in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Abiprubart in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Abiprubart in Rheumatoid Arthritis Drug Details: Abiprubart is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Tegoprubart in Lupus Nephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tegoprubart in Lupus Nephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tegoprubart in Lupus Nephritis Drug Details: Tegoprubart is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tegoprubart in Kidney Transplant Rejection
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tegoprubart in Kidney Transplant Rejection report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tegoprubart in Kidney Transplant Rejection Drug Details: Tegoprubart is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Deupirfenidone in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Deupirfenidone in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Deupirfenidone in Interstitial Lung Diseases (Diffuse Parenchymal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Propagermanium in Focal Segmental Glomerulosclerosis (FSGS)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Propagermanium in Focal Segmental Glomerulosclerosis (FSGS) Drug Details: Propagermanium (DMX-200) as an adjunct therapy with...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Inaxaplin in Focal Segmental Glomerulosclerosis (FSGS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Inaxaplin in Focal Segmental Glomerulosclerosis (FSGS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Inaxaplin in Focal Segmental Glomerulosclerosis (FSGS)Drug Details:Inaxaplin is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VB-119 in Focal Segmental Glomerulosclerosis (FSGS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VB-119 in Focal Segmental Glomerulosclerosis (FSGS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VB-119 in Focal Segmental Glomerulosclerosis (FSGS) Drug Details: VB-119 is...